Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study

被引：1

作者：

Kato, Junji ^{[1
]}

Namikawa, Kenjiro ^{[2
]}

Uehara, Jiro ^{[3
]}

Nomura, Motoo ^{[4
]}

Nakamura, Yasuhiro ^{[5
]}

Uhara, Hisashi ^{[1
]}

Uchi, Hiroshi ^{[6
]}

Yoshikawa, Shusuke ^{[7
]}

Kiniwa, Yukiko ^{[8
]}

Nakamura, Yoshiyuki ^{[9
]}

Miyagawa, Takuya ^{[10
]}

Matsushita, Shigeto ^{[11
]}

Takenouchi, Tatsuya ^{[12
]}

Hatta, Naohito ^{[13
]}

Ohno, Fumitaka ^{[14
]}

Maeda, Taku ^{[15
,16
]}

Fukushima, Satoshi ^{[17
]}

Yamazaki, Naoya

机构：

[1] Sapporo Med Univ, Dept Dermatol, Sapporo, Hokkaido, Japan

[2] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Dermatol Oncol, Tokyo, Japan

[4] Kyoto Univ, Dept Clin Oncol, Kyoto, Japan

[5] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[6] Natl Hosp Org Kyushu Canc Ctr, Dept Dermatooncol, Fukuoka, Japan

[7] Shizuoka Canc Ctr, Div Dermatol, Shizuoka, Japan

[8] Shinshu Univ, Dept Dermatol, Nagano, Japan

[9] Univ Tsukuba, Dept Dermatol, Tsukuba, Ibaraki, Japan

[10] Univ Tokyo, Dept Dermatol, Grad Sch Med, Tokyo, Japan

[11] Natl Hosp Org Kagoshima Med Ctr, Dept Dermatooncol Dermatol, Kagoshima, Japan

[12] Niigata Canc Ctr, Dept Dermatol, Niigata, Japan

[13] Toyama Prefectural Cent Hosp, Dept Dermatol, Toyama, Japan

[14] Kyushu Univ, Dept Dermatol, Fukuoka, Japan

[15] Hokkaido Univ, Dept Plast & Reconstruct Surg, Fac Med, Sapporo, Hokkaido, Japan

[16] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan

[17] Kumamoto Univ, Dept Dermatol & Plast Surg, Kumamoto, Japan

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 187卷 / 04期

关键词：

DISCONTINUATION;

D O I：

10.1111/bjd.21276

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：594 / 596

页数：3

共 50 条

[41] Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study
Ito, Ayumu
Kim, Sung-Won
Matsuoka, Ken-ichi
Kawakita, Toshiro
Tanaka, Takashi
Inamoto, Yoshihiro
Toubai, Tomomi
Fujiwara, Shin-ichiro
Fukaya, Masafumi
Kondo, Tadakazu
Sugita, Junichi
Nara, Miho
Katsuoka, Yuna
Imai, Yosuke
Nakazawa, Hideyuki
Kawashima, Ichiro
Sakai, Rika
Ishii, Arata
Onizuka, Makoto
Takemura, Tomonari
Terakura, Seitaro
Iida, Hiroatsu
Nakamae, Mika
Higuchi, Kohei
Tamura, Shinobu
Yoshioka, Satoshi
Togitani, Kazuto
Kawano, Noriaki
Suzuki, Ritsuro
Suzumiya, Junji
Izutsu, Koji
Teshima, Takanori
Fukuda, Takahiro
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 112 (05) : 674 - 689
[42] Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study
Ayumu Ito
Sung-Won Kim
Ken-ichi Matsuoka
Toshiro Kawakita
Takashi Tanaka
Yoshihiro Inamoto
Tomomi Toubai
Shin-ichiro Fujiwara
Masafumi Fukaya
Tadakazu Kondo
Junichi Sugita
Miho Nara
Yuna Katsuoka
Yosuke Imai
Hideyuki Nakazawa
Ichiro Kawashima
Rika Sakai
Arata Ishii
Makoto Onizuka
Tomonari Takemura
Seitaro Terakura
Hiroatsu Iida
Mika Nakamae
Kohei Higuchi
Shinobu Tamura
Satoshi Yoshioka
Kazuto Togitani
Noriaki Kawano
Ritsuro Suzuki
Junji Suzumiya
Koji Izutsu
Takanori Teshima
Takahiro Fukuda
International Journal of Hematology, 2020, 112 : 674 - 689
[43] A PHASE II STUDY OF THE ANTI-PROGRAMMED CELL DEATH-1 (PD-1) ANTIBODY PENPULIMAB IN PATIENTS WITH METASTATIC NASOPHARYNGEAL CARCINOMA (NPC) WHO HAD PROGRESSED AFTER TWO OR MORE LINES OF CHEMOTHERAPY
Chen, Xiaozhong
Wang, Wei
Zou, Qingfeng
Li, Jingao
Hu, Chaosu
Hu, Chaosu
Lin, Qin
Zhu, Xiaodong
Jiang, Yi
Sun, Yan
Shen, Liangfang
Wang, Lin
Zou, Guorong
Lin, Xiaoyan
Wang, Ying
Lin, Shaojun
Li, Minying
Ao, Rui
Xu, Ruilian
Lin, Haifeng
Wang, Rensheng
Yang, Jiacheng
Song, Weifeng
Wang, Max
Li, Baiyong
Xia, Yu
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A481 - A481
[44] Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer
Ahn, Beung-Chul
So, Jea-Woo
Synn, Chun-Bong
Kim, Tae Hyung
Kim, Jae Hwan
Byeon, Yeongseon
Kim, Young Seob
Heo, Seong Gu
Yang, San-Duk
Yun, Mi Ran
Lim, Sangbin
Choi, Su-Jin
Lee, Wongeun
Kim, Dong Kwon
Lee, Eun Ji
Lee, Seul
Lee, Doo-Jae
Kim, Chang Gon
Lim, Sun Min
Hong, Min Hee
Cho, Byoung Chul
Pyo, Kyoung-Ho
Kim, Hye Ryun
EUROPEAN JOURNAL OF CANCER, 2021, 153 : 179 - 189
[45] Hepatitis B virus infection does not affect the clinical outcome of anti-programmed death receptor-1 therapy in advanced solid malignancies Real-world evidence from a retrospective study using propensity score matching
Zhong, Liting
Zhong, PinShun
Liu, Huafeng
Li, Zelei
Nie, Qihong
Peng, Weiwei
MEDICINE, 2021, 100 (49)
[46] Real-world efficacy of anti-PD-1 antibodies in advanced acral melanoma patients: A retrospective, multicenter study (JAMP study).
Nakamura, Yasuhiro
Namikawa, Kenjiro
Yoshino, Koji
Yoshikawa, Shusuke
Uchi, Hiroshi
Goto, Katsunobu
Nakamura, Yoshiyuki
Fukushima, Satoshi
Kiniwa, Yukiko
Takenouchi, Tatsuya
Uhara, Hisashi
Kawai, Toru
Hatta, Naohito
Funakoshi, Takeru
Teramoto, Yukiko
Otsuka, Atsushi
Doi, Haruki
Ogata, Dai
Matsushita, Shigeto
Yamazaki, Naoya
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[47] Design and rationale of MASTERKEY-115 phase II trial of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in patients with advanced melanoma who progressed on prior anti-programmed cell death-1 (anti-PD-1) therapy.
Chesney, Jason Alan
Milhem, Mohammed M.
Chaney, Marya F.
Gokani, Priya
Snyder, Wendy
Robert, Caroline
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[48] Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study
Li, Tong
Xu, Yu
Sun, Wei
Yan, Wangjun
Wang, Chunmeng
Hu, Tu
Zhang, Xiaowei
Luo, Zhiguo
Liu, Xin
Chen, Yong
PHARMACEUTICALS, 2023, 16 (01)
[49] Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort
Stein, Claire
Burtey, Stephane
Mancini, Julien
Pelletier, Marion
Sallee, Marion
Brunet, Philippe
Berbis, Philippe
Grob, Jean Jacques
Honore, Stephane
Gaudy, Caroline
Jourde-Chiche, Noemie
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (09) : 1664 - 1674
[50] A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results
Chen, X.
Hu, C.
Wang, W.
Zou, Q.
Li, J.
Lin, Q.
Zhu, X.
Jiang, Y.
Sun, Y.
Shen, L.
Wang, L.
Zou, G.
Lin, X.
Wang, Y.
Lin, S.
Li, M.
Ao, R.
Xu, R.
Lin, H.
Wang, R.
ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806

← 1 2 3 4 5 →